NGS of the RMH lymphoma panel revealed multiple mutations in TET2 (n = 4) and DNMT3A (n = 1), which were identical in both LN specimens and microdissected CD8+ T cells, with similar VAFs (Figure 3C; Figure S2A), and these changes were confirmed by Fluidigm PCR/Illumina MiSeq sequencing. This evidence concerns the gene TET2 and lymphoma.